

SENISCA is a senotherapeutics company founded in 2020.

We are a biotech spinout company from the University of Exeter, based in Devon, UK.

Our founders are world leaders in molecular and cellular biology, and have patent-protected an innovation for reversal of cellular senescence, based on our discovery of a 10th hallmark of ageing; dysregulation of alternative splicing.

This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate senescent (aged) cells. At SENISCA, we are using this knowledge to develop a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. SENISCA interventions are oligonucleotide-based.

Key Points

• **Competitive advantage**

SENISCA has discovered a new hallmark of ageing: dysregulation of alternative splicing. This previously unknown, druggable, patented mechanism targets a new pathway to reverse cellular senescence. We are a senotherapeutics company, presenting an alternative to senolytics.

• **Lab facilities**

Protected long term access to world leading molecular biology lab facilities at the University of Exeter Medical School. Including next generation DNA and RNA sequencing platforms, state of the art tissue culture, microscopy and genomics facilities.

• **Experienced team**

An established and highly experienced founding team with expertise in molecular genetics, cell biology, drug discovery and development, and a proven track record in the commercialisation of academic innovation.

• **Markets**

Initial market is skin ageing for proof of principle, transitioning rapidly to pharmaceutical markets, with application to high medical need human diseases.

• **Traction**

Early commercial recognition of SENISCA know-how and our unique ability to 'rejuvenate' human skin, lung and endothelial cells. This is evidenced by pre-incorporation investment/partnership interest from global industry leaders across cosmetics and pharmaceutical sectors.

• **Intellectual Property**

Exclusive licensee of background IP from the University of Exeter, with assignment triggers. Scope for future composition of matter, process and formulation IP as SENISCA enters into different R&D and commercial territory.

Investment Ask

Target: £1m - £1.5m EIS.
Second seed round opening January 2022.

Funding: 12 months cash runway.
Covering: Phase 2 R&D Team expansion and Phase 2 R&D.

Seeking: Executive level team expansion.
Executive Chairman (Pharmaceutical sector background).
Scientific Advisory board expansion (RNA Medicine expertise or Oligonucleotide design and delivery).

SENISCA | Forward thinking to reverse cell ageing

In partnership with:



RILD Building University of Exeter,
Barrack Road, EX2 5DW

General enquiries: +44 (0) 7515 454 146
Info@senisca.com
www.senisca.com

Lorna.Harries@senisca.com
CSO R&D lead, Professor of Molecular
Genetics, University of Exeter

Ben.Lee@senisca.com
CTO Technical Lead

Kirsty.Semple@senisca.com
COO Investor Relations,
Commercial and Finance Lead